What makes Neuralstem so incredible? (CUR)

If you have been following @buyersstrike on Twitter, you might see the occasional tweet about Neuralstem (CUR). Over here at BuyersStrike! HQ we find Neuralstem to be absolutely incredible. It takes a lot to stand above the crowd in the current world of bio-dreck mania. So, what makes this 2006 direct to the OTC-BB company so fascinating?

Well, the thing that makes this company so incredibly amazing (if they can successfully patent and commercialize) could make the company worth more than Apple, Tesla, Google, combined! Yes, more than all of them. Intrigued? Read on….

CUR is a plaything of Bedminster, NJ based bucket shop T.R. Winston. Read the FINRA Broker Check report on T.R. Winston here. But being associated with a schlock shop is not what makes Neuralstem so incredible.

CUR is loved by Brean Capital‘s wretched Jonathan Aschoff. But Jonathan Aschoff likes lots of penny stock garbage dressed in bio-tech bubble clothes. He shamelessly touts Joe Podoloski’s RPRX, the stock promoting goons at INO, the reborn penny scam OHRP, CTSO, and many more. So having a sell side whore like Asshoff strap on his kneepads for the company is not what makes Neuralstem so incredible.

CUR‘s CEO, Richard Garr, is no stranger to controversy. A little over a year ago, in January 2014, while raising money through the above named bucket shop, TR Winston, Garr, in an (at best) ethically dubious move, tweeted about a patient in the Neuralstem ALS clinical trial. Crain’s NY writer Aaron Elstein, in an excellent piece available here, investigated the tweet activity and the TR Winston – Neuralstem connection. Yet this is still not what makes Neuralstem so incredible.

CUR announced today highly misleading results of that very same, incredibly poorly designed, ALS clinical trial. Read their spin-laden bullshit press release here. While Neuralstem tries valiantly to obfuscate the real results by offering a bizarre post-hoc grouping of patients, TheStreet.com’s Adam Feuerstein sees through CUR’s bullshit in an article available here. Lots of companies put out bullshit press releases, so that is not what makes Neuralstem so incredible.

But hidden in that press release is the gem that makes CUR so incredible. Here is a direct quote, emphasis ours:

GERMANTOWN, Md., March 12, 2015 /PRNewswire/…

The average ALSFRS score for responders at 9 months after treatment was 37. Non-responders scored an average of 14. These scores represent 93%, versus 35%, of the baseline score retained, respectively, by the responders versus non-responders at 9 months, which is a statistically significant difference.

Keen observers of Neuralstem, or just anyone who can use Yahoo! Finance, probably recall that in August of last year, CUR announced that the final patient in the Phase 2 ALS trial was treated. The relevant section is quoted below, emphasis ours:

GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

Using a little advanced math, lets count 9 months forward from August 4th. September, October, November, December, January, February, March, April, and May. How can the company report 9 month trial results in early March 2015 if the last patient was only treated in early August 2014? The 9 month results cannot possibly have been compiled yet.

Neuralstem might not have cured ALS, but they just may have solved the mystery of time travel! Imagine the possibilities. And that, dear readers, is what makes CUR truly incredible!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.


  1. About time! I have been anxiously awaiting your next rant! Can’t believe some of the crap that’s out there. Thanks for sniffing out the BS!

  2. I guess you haven’t realized the last patient is at 6 months, and they included the patient in the non-responder catagory. But you and adam fkstain are the medical experts right? Thank god we have the non-qualified to see right through the bullshit. I’ll tell you one thing, this article is complete bullshit, and reminds me of the conspiracy theorists garbage.

    [@afjim742 – Wake up man. One cannot report 9 month results if the last patient was treated only 6 months ago, and one cannot arbitrarily determine a patient’s response at 9 months when only 6 months have elapsed. CUR is a scam run by scoundrels preying on the stupidity of retail dolts. Don’t be such a willing victim. – Editor]

  3. Could you please give me a hint on what is wrong with CTSO?

    [@OneDayTradeLeft – Start with the fact that CTSO is a reverse merger. In the modern day reverse mergers into BB/Pink shells is the lowest level of the financial world. Reverse mergers are the tools of conmen, thieves, criminals, and management teams either stupid, complicit or criminals themselves. If one follows the simple rule of never investing in reverse merger, one greatly reduce one’s risk of being conned. Remember the BuyersStrike! Maxim: “Reverse mergers are scams. All of them. In one way or another.” – Editor]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.